专利检索 ap:("Xenon Genetics, Inc." OR "Warner-Lambert Company LLC") AND inv:"BROWNLIE, Alison, J." 第 1 页

1.

发明公开
NOVEL THERAPEUTIC TARGET FOR TREATING VASCULAR DISEASES, DYSLIPIDEMIAS AND RELATED DISORDERS 审中-公开
标题翻译：新靶点用于治疗GEFÜSSKRANKHEITEN，DYSLIPIDÜMIEN及相关疾病

公开(公告)号：EP1551856A2

公开(公告)日：2005-07-13

申请号：EP03762177.8

申请日：2003-06-27

申请人： Xenon Genetics, Inc. , Warner-Lambert Company LLC

发明人： BROWNLIE, Alison, J. , TAFURI,Sherrie, Rae , BRINKMAN, Ryan, R. , CHAGNOVICH, Daniel , CHATTERJEE, Aurobindo , DONALDSON, Gary, C. , DUBE, Marie-Pierre , GOLDBERG, Yigal, P. , JERVA, Leonard, F. , LAFRENIER, Ronald, G. , LUDWIG, Erwin , SAMUELS, Mark, E. , WU, Chenyan , HAYDEN, Michael, R.

IPC分类号： C07H21/04 , C12Q1/00 , C12Q1/68 , C12P21/06 , C12N15/63

CPC分类号： C07K14/47

摘要： The invention features compositions and methods for modulating HDL levels and/or treating a vascular disease, dyslipidemia or a related disorder in a patient in need thereof. The invention also includes methods for identifying therapeutic agents for such treating disorders based on the identification of novel therapeutic targets herein. The invention also includes diagnostic and pharmacogenomic compositions and methods which employ the therapeutic targets named herein.

2.

发明公开
STEAROYL-COA DESATURASE TO IDENTIFY TRIGLYCERIDE REDUCING THERAPEUTIC AGENTS 有权
标题翻译：硬脂酰COA脱氢酶一种判别TRIGLYCERIDREDUKTIONSTHERAPEUTIKA

公开(公告)号：EP1315831A2

公开(公告)日：2003-06-04

申请号：EP01920143.3

申请日：2001-02-23

申请人： Xenon Genetics Inc. , WISCONSIN ALUMNI RESEARCH FOUNDATION , University of British Columbia

发明人： BROWNLIE, Alison, J. , HAYDEN, Michael, R. , ATTIE, Alan, D. , NTAMBI, James, M. , GRAY-KELLER, Mark, P. , MIYAZAKI, Makoto

IPC分类号： C12Q1/26

CPC分类号： C12N15/1137 , A61K31/00 , A61K31/201 , A61K31/426 , A61K31/4439 , A61K48/00 , C07K16/40 , C12N9/0083 , C12Q1/26 , G01N2333/90245 , Y10S514/866 , Y10S514/909

摘要： The use of screening assays based on the role of human stearoyl-CoA desaturase-1 ('hSCD1') in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids., wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.